.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
Novartis
Farmers Insurance
QuintilesIMS
Medtronic
McKesson
Dow
Cipla
Moodys

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,715,623

« Back to Dashboard

Which drugs does patent 8,715,623 protect, and when does it expire?


Patent 8,715,623 protects TOBI PODHALER and is included in one NDA.

This patent has fifteen patent family members in fourteen countries.

Summary for Patent: 8,715,623

Title:Pulmonary delivery of aminoglycoside
Abstract: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
Inventor(s): Tarara; Thomas E. (Burlingame, CA), Weers; Jeffry G. (Half Moon Bay, CA), Venthoye; Geraldine (Foster City, CA)
Assignee: Novartis AG (Basel, CH)
Application Number:11/981,986
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Dosage form; Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
NovartisTOBI PODHALERtobramycinPOWDER;INHALATION201688-001Mar 22, 2013RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,715,623

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,368,102Pulmonary delivery of aminoglycosides► Subscribe
9,421,166Pulmonary delivery of aminoglycoside► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,715,623

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI324518► Subscribe
Taiwan200301131► Subscribe
Slovenia1458360► Subscribe
Portugal1458360► Subscribe
MexicoPA04005865► Subscribe
South Korea100958235► Subscribe
South Korea20040075897► Subscribe
Japan2005514393► Subscribe
Japan5351120► Subscribe
Japan2011001389► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
US Department of Justice
Covington
QuintilesIMS
Farmers Insurance
Johnson and Johnson
Teva
Healthtrust
Citi
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot